The World Desk · slice 04

Health & Bio Desk

Approvals, trials, and the research frontier — where a single regulatory decision reprices a molecule, a company, or a standard of care. This desk reads the health slice of the lattice, from FDA actions to the oncology literature.

$1.6T: annual sales of the global pharmaceutical market — industry estimates.

As of 2026-08-31 · live snapshot.

What the money says

Capital markets read as belief sensors — credit, volatility, and the desk’s own equity basket. Context, not a signal to act on.

High-yield credit spreads edged narrower 12 bps this week to 2.63% — lenders are pricing less risk.

  • High-yield credit spread: 2.63% · down 12 bps over 5 sessions · as of 2026-08-27
  • 10-year Treasury yield: 4.67% · down 2 bps over 5 sessions · as of 2026-08-27
  • Biotech basket (XBI): $162.38 · down 2.0% over 5 sessions · as of 2026-08-28

Public market data, cited as context — not investment advice.

Contracts & awards

From the federal public record (SAM.gov · USAspending): the money actually moving, not the press release about it.

Also tracked on this desk

Subjects whose coverage concentrates in this desk’s domains, counted from the committed corpus — story counts, not estimates.

colorectal cancer · 1,629 stories →KRAS · 357 stories →immunotherapy · 321 stories →ctDNA · 174 stories →wang · 156 stories →lung cancer · 146 stories →clinical trials · 118 stories →chen · 111 stories →pancreatic cancer · 101 stories →braf · 91 stories →zhang · 89 stories →egfr · 77 stories →

On the desk wire

Names native to this desk moving across the whole lattice right now. Click through for momentum, coverage, and the read.

In 9 domains · 23 mentions today

FDA

In 9 verticals across 9 domains

In the coverage

The desk’s read of what its sources reported most recently. Distilled from 939 fresh items across 362 sources on this desk’s beat — the full lattice feeds every desk; these are the top reads.

Questions the desk is watching

KRAS: is the next trial readout a breakthrough or a setback?ctDNA: is minimal-residual-disease testing about to change the standard of care in colorectal cancer?Immunotherapy: where does the next approval most likely come?FDA to issue compliance guidance for animal-derived thyroid products by August 2026 — what does the record show?
THE HEALTH & BIO DESK BRIEF

What this desk sees, in your inbox: the record, the moves, and the read, written for managers whose portfolio is the world.

Informational only — not investment advice. Market-size figures are editorial estimates with sources as noted; contract and award lines are drawn from public federal records via our tracked pipelines.